Product Description
KI1001(Circadin, Prolonged release tablet which contains melatonin) has showed its efficacy to improve sleep quality in over 55 years old primary insomnia patients.
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kuhnil
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Insomnia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02087722 |
13-CC-8303 | P3 |
Completed |
Insomnia |
2014-01-01 |
2019-03-20 |
Treatments |
|
NCT01450228 |
10-CC-8302 | P3 |
Completed |
Insomnia |
2012-03-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|